Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Alzheimer's Disease Proteins in the Brain and Blood of Older Adults With Normal Cognition

Start: August 27, 2021
End: September 2022
Enrollment: 200

What Is This Study About?

This study will compare the amount of amyloid protein in the brain with the amounts of other proteins associated with developing Alzheimer's disease, including tau, in the blood of older adults with normal cognition. Participants will have their brain imaged with a PET scan and provide blood samples for protein analysis and genetic testing for APOE, a gene associated with Alzheimer's risk. Researchers will use the information collected to create a database for future studies on Alzheimer's.

Do I Qualify To Participate in This Study?

Minimum Age: 70 Years

Maximum Age: N/A

Must have:

  • Normal cognition, based on cognitive testing at study screening
  • Male participants must:
    • Not donate sperm for the study duration
    • Commit to using two methods of contraception for the study duration, if partner is of childbearing potential

Must NOT have:

  • Participation in another clinical trial for an experimental drug or device within one month prior to study screening, unless approved by the study investigator
  • Previously taken any experimental or approved medication targeting amyloid or tau
  • Pregnant, lactating, or breastfeeding
  • Evidence of a serious medical illness that could interfere with study (e.g., cancer, intestinal, heart, liver, kidney, lung, blood, hormone, neurological, or immune disorder)
  • Any condition that could make having the following study procedures unsafe:
    • PET scan using a radioactive tracer that binds to amyloid (e.g., pregnancy, sensitivity to materials being used, poor vein access, prior radiation exposure that when combined with study PET scan would exceed radiation limits)
    • Blood sampling (e.g., infection or injury at vein puncture site, veins unsuitable for needle insertion)

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Lianne Ramia

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Connecticut
Invicro
New Haven, CT 06510
Recruiting
David Russell, M.D., Ph.D

Who Sponsors This Study?

Lead: Invicro

Source: ClinicalTrials.gov ID: NCT05164536

 

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health